Recent Finacing
Recent Raise
Singapore biotech developing antibodies that block an ECM‑degrading protein exposed by the GALA glycosylation pathway to treat solid tumors and arthritic disorders; conducting target validation and preclinical development.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors